R
Radar Therapeutics
Biotech & Life Sciences · Berkeley, United States · Founded 2022
Ribonucleic acid sensing technology for therapies that identify and eliminate pathogenic cells based on their genetic activity MoreLess
Radar Therapeutics is a biotechnology company that develops programmable precision therapeutics. The company's technology is based on ribonucleic acid (RNA) sensing, which allows for the creation of therapies that can identify and target pathogenic cells based on their specific transcriptional signatures or genetic activity. This approach utilizes messenger RNA (mRNA) to create smart programmable medicines.
The company, founded in 2022, recently secured $13.4 million in an oversubscribed seed financing round. This funding is intended to advance the development of its platform and pipeline of therapeutic candidates. The technology has the potential to address a wide range of diseases by precisely targeting unhealthy cells while leaving healthy ones untouched. The business model likely involves partnerships or licensing agreements with larger pharmaceutical firms to bring these treatments through clinical trials and to the market.
Keywords: RNA sensing, precision therapeutics, mRNA technology, pathogenic cells, transcriptional signatures, programmable medicine, biotechnology, seed funding, genetic activity, targeted therapy
Company overview
Radar Therapeutics company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2022
- Headquarters
- Berkeley, United States
- Employees
- 17
- Open positions
- None listed
- Dealroom signal
- 68.6
Valuation & funding
Radar Therapeutics funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SEED✓Equity / VC | May 2024 | $13M | $54M | Pear Ventures · Eli Lilly · NFX · KdT Ventures | ↗ |
| GRANTOther financing | May 2023 | $0 | — | Pear Ventures | ↗ |
| SPINOUT✓Other financing | Jan 2022 | $0 | — | Massachusetts Institute of Technology · Stanford University | — |
Financials
Workforce over time
Available workforce history. Financial fields without reported data are omitted.
| Year | Employees |
|---|---|
| 2026 | 17 |
| 2025 | 15 |
| 2024 | 16 |
Growth signals
Radar Therapeutics website traffic
Latest recorded traffic for Radar Therapeutics is 2.2K monthly website visits, down 18.5% over the last three months. Radar Therapeutics's team grew 13.3% over the past year.
Comparisons
Radar Therapeutics compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Radar Therapeutics's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Radar Therapeutics has talent and traffic
team presence
In the news
Latest news about Radar Therapeutics
Recent press, funding announcements, and product moves mentioning Radar Therapeutics — open to read from the original sources.
Market sentiment
What the market is saying about Radar Therapeutics
An AI-synthesized read of the highest-engagement posts about Radar Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Radar Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.